Literature DB >> 11322501

Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

J D Veldhuis1, W S Evans, C Y Bowers, S Anderson.   

Abstract

Estrogen is the proximate sex steroid sustaining GH secretion throughout the human life span in both sexes. However, very little is known about the specific neuroendocrine mechanisms by which estrogen activates and maintains GH secretion in the young or aging human. The identification of somatostatin in 1973 as a key negative peptidyl regulator of the GH axis and the discovery of GH-releasing hormone (GHRH) in 1982 as a dominant feedforward agonist of GH secretion provided an initial basic science foundation for exploring sex-steroid control of the GH-IGF-1 axis. Although GH-releasing peptides (GHRPs) were first recognized in 1977-1981, subsequent cloning of hypothalamopituitary receptors transducing potent secretagogue actions of GHRPs in 1996 and of an endogenous ligand for this effector pathway in 1999 now extend the framework for examining the mechanisms of estrogen-driven GH secretion in aging. Herein, we review several novel and multifaceted interactions in postmenopausal women between estrogen and GHRP-2. We combine these observations into a simplified construct of GH-axis neuroregulation comprising the somatostatin, GHRH, and GHRP effector pathways, as well as GH and IGF-1 autofeedback. We suggest the thesis that estrogen controls the interfaces among these pivotal regulatory peptides in hyposomatotropic postmenopausal individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11322501     DOI: 10.1385/ENDO:14:1:045

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  306 in total

1.  Intrahypothalamic growth hormone feedback: from dwarfism to acromegaly in the rat.

Authors:  E Pellegrini; D F Carmignac; M T Bluet-Pajot; F Mounier; P Bennett; J Epelbaum; I C Robinson
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

Review 2.  Neuroendocrine control of pulsatile growth hormone release in the human: relationship with gender.

Authors:  J D Veldhuis
Journal:  Growth Horm IGF Res       Date:  1998-04       Impact factor: 2.372

Review 3.  Neural control of somatotropic function.

Authors:  E E Müller
Journal:  Physiol Rev       Date:  1987-07       Impact factor: 37.312

4.  Ultradian oscillations in somatostatin and growth hormone-releasing hormone mRNAs in the brains of adult male rats.

Authors:  P Zeitler; G S Tannenbaum; D K Clifton; R A Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

5.  Single exposure to testosterone in adulthood rapidly induces regularity in the growth hormone release process.

Authors:  J C Painson; J D Veldhuis; G S Tannenbaum
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-05       Impact factor: 4.310

6.  Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

Authors:  I Shimon; X Yan; J E Taylor; M H Weiss; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

7.  Defective hypothalamic growth hormone (GH)-releasing hormone activity may contribute to declining GH secretion with age in man.

Authors:  E C degli Uberti; M R Ambrosio; S G Cella; A R Margutti; G Trasforini; A E Rigamonti; E Petrone; E E Müller
Journal:  J Clin Endocrinol Metab       Date:  1997-09       Impact factor: 5.958

8.  Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

Authors:  M L Vance; D L Kaiser; W S Evans; R Furlanetto; W Vale; J Rivier; M O Thorner
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

9.  Augmentation of growth hormone secretion during puberty: evidence for a pulse amplitude-modulated phenomenon.

Authors:  N Mauras; R M Blizzard; K Link; M L Johnson; A D Rogol; J D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  1987-03       Impact factor: 5.958

10.  Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.

Authors:  C A Jaffe; P J Ho; R Demott-Friberg; C Y Bowers; A L Barkan
Journal:  J Clin Endocrinol Metab       Date:  1993-12       Impact factor: 5.958

View more
  5 in total

Review 1.  Role of hormones in the pathogenesis and management of sarcopenia.

Authors:  Hosam K Kamel; Diana Maas; Edmund H Duthie
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Estroprogestinic pill normalizes IGF-I levels in acromegalic women.

Authors:  R Cozzi; M Barausse; S Lodrini; G Lasio; R Attanasio
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

Review 3.  Human GH pulsatility: an ensemble property regulated by age and gender.

Authors:  J D Veldhuis; C Y Bowers
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

4.  The association of breast mitogens with mammographic densities.

Authors:  N F Boyd; J Stone; L J Martin; R Jong; E Fishell; M Yaffe; G Hammond; S Minkin
Journal:  Br J Cancer       Date:  2002-10-07       Impact factor: 7.640

Review 5.  Sex-steroid modulation of growth hormone (GH) secretory control: three-peptide ensemble regulation under dual feedback restraint by GH and IGF-I.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.